On May 26, 2026, Genprex, Inc. announced the publication of positive clinical data at the 2026 ASCO Annual Meeting, highlighting biomarkers that may predict treatment efficacy for its lung cancer drug, Reqorsa. The data showed correlations between high Trop-2 and low PTEN levels with prolonged Progression Free Survival in patients with Non-Small Cell Lung Cancer.